Skip to Main Content

Paper Details

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.
Nat Commun
67
2019
DS, Down syndrome, IDO1, IFN, IFN receptors, Immune cells, KP, T21, Trisomy 21, chromosome 21, immunosuppression, interferon, interferon receptors, kynurenine, mouse, neurotoxicity, people, plasma, quinolinic acid, tryptophan
Author NameAffiliation
Rani K PowersLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus
Rani K PowersUniversity of Colorado Anschutz Medical Campus
Rani K PowersUniversity of Colorado Anschutz Medical Campus
Rachel Culp-HillUniversity of Colorado Anschutz Medical Campus
Angelo D'AlessandroLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus
Angelo D'AlessandroUniversity of Colorado Anschutz Medical Campus
Angelo D'AlessandroLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus
Angelo D'AlessandroUniversity of Colorado Anschutz Medical Campus
James C CostelloUniversity of Colorado Anschutz Medical Campus
James C CostelloUniversity of Colorado Anschutz Medical Campus
  • 1 - 10

Datasets

Release 1.2